ABSTRACT
Introduction: Zygomycetes consisting of Mucorales order is a group of fungal infections. These species cause life threatening opportunistic fungal infections mucormycosis. This infection is highly prevalent in immunocompromised. During the 2 nd wave of Covid 19 pandemic corticosteroid treatment was used which has been linked to development of Mucormycosis. In our tertiary care teaching hospital we saw that patients suffering from Covid-19 infections developed mucormycosis. We present these cases in our study. To study the clinical, demographical,and Laboratory parameters in Covid-19 patients with Mucormycosis. Material(s) and Method(s): Retrospective Study. All biopsy proven cases of Mucormycosis (which developed after Covid-19 infection) were included. Relevant Clinical Demographics and Laboratory data was retrieved from the available case sheets. The data was tabulated in Excel sheet and further reviewed. Result(s): A total of 22 patients were diagnosed as suffering from mucormycosis majority were unvaccinated. 11 patients out of 22 (50%) started manifesting mucormycosis within one week of COVID infection. All the patients who had only single comorbidity (22.72%) suffered from mild disease and patient who had more than one comorbidity suffered from moderate (27.27%) to severe (50%) COVID infection. Conclusion(s): It is suggested that patients with Covid-19 infection are at risk for development of opportunistic fungal infections like Mucormycosis. Hence the physicians who are involved in treating such patients must be mindful of the fact that mucormycosis can develop in them. Histopathology helps in establishing a concrete diagnosis of Mucormycosis.Copyright © 2022 Wolters Kluwer Medknow Publications. All rights reserved.
ABSTRACT
Background: The SARS-CoV-2 associated with bacterial infection represents a serious public health challenge. Recently, there is a remarkable increase in the number of researches that confirms the effect of Helicobacter pylori on pulmonary diseases. Aim(s): The goal of this research was to see how H. pylori affected the presentation of COVID-19 infections as a prospective risk factor. Material(s) and Method(s): This research was conducted in Babylon, Iraq, from January 1, 2022, to March 5, 2022. A total of 180 people were engaged in this study, with 90 patients identified with SARS-CoV-2 by polymerase chain reaction testing and 90 people serving as a control group. Antibody screening assays on blood samples were used to look for antibodies against H. pylori. The samples were processed for complete blood count and ABO blood group. Result(s): COVID-19 infection was more frequent in females than in males, especially between 31 and 45 years. When compared to healthy people, COVID-19 patients had a higher white blood cell count (P = 0.0001) and a lower lymphocyte count (P = 0.0001). H. pylori and COVID-19 have been found to have a strong relationship, especially in females. When comparing patients to healthy people, blood group A is the most common. Conclusion(s): People with H. pylori infections are considerably more sensitive to COVID-19 than people without H. pylori infections (P = 0.011). In combination with SARS-CoV-2, IgG for H. pylori might be a risk factor.Copyright © 2023 Journal of Medical Society Published by Wolters Kluwer-Medknow.
ABSTRACT
Since COVID-19 disease spreads very rapidly in society, the effect of genetic blood types on people catching the disease should be investigated. In this study, the aim was to investigate whether there is a relationship between ABO and Rh blood group systems and COVID-19 disease, severity and frequency. The blood groups of 16913 patients treated with the diagnosis of COVID-19 between March 10, 2020 and March 31, 2021 and 23141 control cases were compared retrospectively. The blood group distributions of th e patients treated in the intensive care unit were examined. Among the COVID-19 positive patients, the percentage of patients with blood group A (45.04%) was statistically significantly higher than the percentage of patients with blood group O (26.69%), b lood group B (17.16%) and blood group AB (8.09%). The percentage of COVID-19 positive patients who were Rh positive (88.06%) was statistically significantly higher than the percentage who were Rh negative (11.93%). Among the COVID-19 patients, 7354 (43.48%) of 16913 patients were hospitalized and treated in the intensive care unit. The distribution of patients treated in the intensive care unit by blood group was blood group A 46.0%, blood group O 28.95%, blood group B 17.36%, and blood group AB 7.65%. In the intensive care unit, 6445 were Rh (+) (87.63%) and 909 were Rh (-) (12.36%). It was determined that the risk of COVID-19 disease is associated with ABO and Rh blood groups. We think that blood groups have an important role in the follow-up and treatment of COVID-19 disease. Copyright © 2022, Yuzuncu Yil Universitesi Tip Fakultesi. All rights reserved.
ABSTRACT
Context: COVID-19 is an emerging infectious disease and blood group has an influence on the susceptibility of infectious diseases including COVID-19. Aim: The present study was conducted with the aim to observe the association of ABO blood groups with COVID-19. Setting and Design: A nonexperimental hospital-based case-control research design was adopted to conduct the study with 200 COVID-19 patients who met the inclusion criteria. Subjects and Methods: Informed consent was obtained from the participants after explained the purpose of the study. Data were collected by interview method using a structured questionnaire and medical record was also utilized to collect the data. The collected data were prepared for analysis using Microsoft Excel. Statistical Analysis Used: Both descriptive and inferential statistical methods were used to analyze the data using the software SPSS 16 version. Results: The results of the study revealed that out of 200 participants, 83 (42.5%) belonged to A+, 68 (33%) belonged to B+, 7 (14%) belonged to O+, 18 (9%) belonged to AB +, and 4 (%) belonged to A-blood group. Conclusion: The findings of the current study concluded that the prevalence rate of COVID-19 was higher among non-O blood group than in the O blood group and the blood group is associated with the severity of illness. Despite further studies on the individuals with confirmed exposure to COVID-19 infection should be conducted with large samples to generalize the findings. © 2022 Wolters Kluwer Medknow Publications. All rights reserved.